Prognostic value of miR-21 in colorectal cancer, pancreatic ductal adenocarcinoma, and esophageal squamous cell carcinoma: updated systematic review and meta-analysis
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf309 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Oncologist, 2025. Verfasst von Jing Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, The Shanxi Province People's Hospital, Taiyuan, China. Hauptthemen laut MEDLINE: MicroRNAs, Carcinoma, Pancreatic Ductal, Esophageal Squamous Cell Carcinoma, Pancreatic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
This study aims to conduct a systematic review of the prognostic value of miR-21 expression levels in patients with colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), and esophageal squamous cell carcinoma (ESCC). Methods and Results We searched the PubMed, Embase, and CENTRAL databases for relevant studies published up to August 25, 2023. Sixteen studies, totaling 3096 patients, were included. High miR-21 expression was associated with higher hazard ratio (HR) values and decreased overall survival (OS) in CRC and PDAC, but this effect was not statistically significant in ESCC. The pooled HRs for CRC, PDAC, and ESCC were 1.54 (95% confidence interval [CI]: 1.14-2.07; P = 0.004; I2 = 71%), 2.11 (95% CI: 1.81-2.46; P < 0.001; I2 = 0%), and 1.79 (95% CI: 0.82-3.92; P = 0.15; I2 = 75%), respectively. Patients with high miR-21 expression had higher HR values and decreased disease-free survival (DFS) compared to those with low miR-21 expression in all three cancer types. The pooled HRs for CRC, PDAC, and ESCC were 1.88 (95% CI: 1.36-2.60; P < 0.001; I2 = 59%), 2.04 (95% CI: 1.34-3.11; P < 0.001; I2 = 17%), and 1.77 (95% CI: 1.04-3.03; P = 0.04; I2 = 36%), respectively.
Conclusion
Elevated miR-21 expression levels are associated with poorer OS and DFS in patients with CRC, pancreatic cancer, and esophageal cancer. However, due to heterogeneity in the results, further large-sample, high-quality studies are needed to validate these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Colorectal Surgery, The Shanxi Province People's Hospital, Taiyuan, China.
- Department of Ultrasound Medicine, The Shanxi Province People's Hospital, Taiyuan, China.
ORCID-Profile: Chunbao Zhai
Zitieren
APA
Huang, J., He, Q., Wang, J., & Zhai, C. (2025). Prognostic value of miR-21 in colorectal cancer, pancreatic ductal adenocarcinoma, and esophageal squamous cell carcinoma: updated systematic review and meta-analysis. The Oncologist. https://doi.org/10.1093/oncolo/oyaf309
Vancouver
Huang J, He Q, Wang J, Zhai C. Prognostic value of miR-21 in colorectal cancer, pancreatic ductal adenocarcinoma, and esophageal squamous cell carcinoma: updated systematic review and meta-analysis. The Oncologist. 2025. doi:10.1093/oncolo/oyaf309
BibTeX
@article{Huang2025,
author = {Huang, Jing and He, Qiang and Wang, Jufang and Zhai, Chunbao},
title = {Prognostic value of miR-21 in colorectal cancer, pancreatic ductal adenocarcinoma, and esophageal squamous cell carcinoma: updated systematic review and meta-analysis},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf309}
}
EUVIMED